Abstract:Introduction: Major neurocognitive disorder (or simply Dementia) is one of the main causes of disability and burden disease to caregivers and the health system, and a frequent cause of mortality worldwide. Alzheimer`s disease (AD) is the most common type (60-70%). AD is a progressive neurodegenerative disorder characterized by amyloid-β (Aβ) deposition, causing neuronal and synaptic loss with subsequent cognitive disfunction. There is cumulating evidence that sleep disturbances are associated with several pathological conditions, and AD is one of these. The prevalence and severity of sleep disorders is significant in AD patients, with sleep disturbances often precede its clinical diagnosis in many years. Some studies focus on possible mechanisms by which (abnormal) sleep participate in AD pathogenesis, and concluded individuals with sleep disturbances are at higher risk of developing dementia. Objectives: To highlight the current evidence on whether sleep disorders could precipitate or accelerate the clinical course of AD. Methods: Non-systematic review about sleep abnormalities and AD pathogenesis. Results: Several authors described a two-way relationship between sleep and amyloid pathology - sleep deprivation would lead to increased production and decreased clearance of Aβ; once Aβ is accumulated it results in more disrupted sleep, with an increase of Aβ production during wakefulness and a decrease of its clearance during sleep. Recent data showed that sleep continuity and architecture (decreased total sleep time, slow-wave sleep, and REM sleep) are disturbed in AD patients. Otherwise, sleep deprivation may be associated with decreased glymphatic system clearance, leading to accumulation of neurotoxic proteins, particularly Aβ (and tau). It`s also associated with proinflammatory states due to accumulation of reactive oxygen species, nucleotides and proteins during wakefulness, which leads to immune response that causes neuronal dysfunction and cellular death. Insomnia and sleep deprivation were also associated with activation of complement pathway and immunoglobulins secretion. Many studies suggest chronic sleep disruption changes blood–brain barrier structure and function leading to Aβ accumulation. Conclusions: There is emerging evidence that points sleep disturbances as both a potential marker for AD pathology and risk predictor of developing the disease. Future investigations should evaluate the relationship between specific sleep disorders and AD physiopathology.

Decreased Melatonin Levels in Postmortem Cerebrospinal Fluid in Relation to Aging, Alzheimer's Disease, and Apolipoprotein E-epsilon4/4 Genotype.

Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels.

Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages.

Melatonin and Sleep Disturbances in Alzheimer's Disease.

Melatonin regulates A production/clearance balance and A neurotoxicity: A potential therapeutic molecule for Alzheimer's disease

Melatonin: A potential nighttime guardian against Alzheimer's

Apolipoprotein E Influences Melatonin Biosynthesis by Regulating NAT and MAOA Expression in C6 Cells.

1008 Daytime Sleepiness Is Associated with Increased Cerebrospinal Fluid Tau Proteins in Alzheimer’s Disease

Circadian Rhythm of Melatonin and Alzheimer'S Disease

Melatonin decreases levels of S100β and NFκ B, increases levels of synaptophysinina rat model of Alzheimer's disease

Melatonin in Alzheimer's Disease: Literature Review and Therapeutic Trials

Sleep in Alzheimer's disease: a systematic review and meta-analysis of polysomnographic findings

The Therapeutic Potential of Melatonin in Alzheimer's Disease: A Comprehensive Review

Sleep in Alzheimer’s disease: a systematic review and meta-analysis of polysomnographic findings

Brain washing and neural health: role of age, sleep, and the cerebrospinal fluid melatonin rhythm

Decreased Vasopressin Gene Expression in the Biological Clock of Alzheimer Disease Patients with and Without Depression

Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin

Constant illumination induces Alzheimer-like damages with endoplasmic reticulum involvement and the protection of melatonin

Degeneration and energy shortage in the suprachiasmatic nucleus underlies the circadian rhythm disturbance in ApoE −/− mice: implications for Alzheimer’s disease

P155: Circadian Rhythms and Alzheimer's Disease

Melatonin Attenuates Scopolamine-Induced Memory/Synaptic Disorder by Rescuing EPACs/miR-124/Egr1 Pathway